Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Bevacizumab goes anterior: antiangiogenic therapy at cornea and conjunctiva].

Literature DB >> 19396448

[Bevacizumab goes anterior: antiangiogenic therapy at cornea and conjunctiva].

C Cursiefen¹.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2009 PMID： 19396448 DOI： 10.1007/s00347-009-1933-1

Source DB: PubMed Journal: Ophthalmologe ISSN： 0941-293X Impact factor: 1.059

× No keyword cloud information.

13 in total

Review 1. Corneal (lymph)angiogenesis--from bedside to bench and back: a tribute to Judah Folkman.

Authors: Birgit Regenfuss; Felix Bock; Anand Parthasarathy; Claus Cursiefen
Journal: Lymphat Res Biol Date: 2008 Impact factor: 2.589

2. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.

Authors: Claus Cursiefen; Jingtai Cao; Lu Chen; Ying Liu; Kazuichi Maruyama; David Jackson; Friedrich E Kruse; Stanley J Wiegand; M Reza Dana; J Wayne Streilein
Journal: Invest Ophthalmol Vis Sci Date: 2004-08 Impact factor: 4.799

3. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study.

Authors: Dilraj S Grewal; Rajeev Jain; Harsh Kumar; Satinder Pal Singh Grewal
Journal: Ophthalmology Date: 2008-08-09 Impact factor: 12.079

4. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial.

Authors: Claus Cursiefen; Felix Bock; Folkert K Horn; Friedrich E Kruse; Berthold Seitz; Vincent Borderie; Beatrice Früh; Michael A Thiel; Frank Wilhelm; Bernard Geudelin; Isabelle Descohand; Klaus-Peter Steuhl; Angela Hahn; Daniel Meller
Journal: Ophthalmology Date: 2009-07-29 Impact factor: 12.079

5. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation.

Authors: Bjoern O Bachmann; Felix Bock; Stanley J Wiegand; Kazuichi Maruyama; M Reza Dana; Friedrich E Kruse; Elke Luetjen-Drecoll; Claus Cursiefen
Journal: Arch Ophthalmol Date: 2008-01

6. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.

Authors: Felix Bock; Jasmine Onderka; Tina Dietrich; Björn Bachmann; Friedrich E Kruse; Matthias Paschke; Grit Zahn; Claus Cursiefen
Journal: Invest Ophthalmol Vis Sci Date: 2007-06 Impact factor: 4.799

7. Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension.

Authors: Ludwig M Heindl; Tanja N Hofmann; Harald L J Knorr; Carmen Rummelt; Falk Schrödl; Ursula Schlötzer-Schrehardt; Leonard M Holbach; Gottfried O H Naumann; Friedrich E Kruse; Claus Cursiefen
Journal: Invest Ophthalmol Vis Sci Date: 2009-01-17 Impact factor: 4.799

[Bevacizumab goes anterior: antiangiogenic therapy at cornea and conjunctiva].

Review 1. Corneal (lymph)angiogenesis--from bedside to bench and back: a tribute to Judah Folkman.

2. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.

3. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study.

4. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial.

5. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation.

6. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.

7. Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension.

8. [Antiangiogenic therapy for pterygium recurrence].

Review 9. [Antiangiogenic treatment for neovascular glaucoma and after filtering surgery].

10. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.

1. [Pterygium. Etiology, clinical aspects and novel adjuvant therapies].